Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

(2022) Julie A. Zorn et al.   Scientific Reports

PD-L1 Antibody Pharmacokinetics and Tumor Targeting in Mouse Models for Infectious Diseases

(2022) Gerwin G. W. Sandker et al.   Frontiers in Immunology

Overcoming the challenges associated with CD3+ T-cell redirection in cancer

(2021) Ajit Singh et al.   BRITISH JOURNAL OF CANCER

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors

(2021) Jim Middelburg et al.   Cancers

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

(2021) Zheng Tian et al.   Journal of Hematology & Oncology

Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas

(2021) Ross Salvaris et al.   Journal of Personalized Medicine

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

(2021) Lauric Haber et al.   Scientific Reports

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies

(2021) Mathilde Poussin et al.   Journal for ImmunoTherapy of Cancer

Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies

(2021) Gihoon You et al.   Vaccines

Macropinocytosis drives T cell growth by sustaining the activation of mTORC1

(2020) John C. Charpentier et al.   Nature Communications

Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition

(2020) Evdokia Michalopoulou et al.   Cell Reports

Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

(2020) Hui Yi Chew et al.   CELL

Biodistribution of a CD3/EpCAM bispecific T-cell engager is driven by the CD3 arm

(2020) Frans V. Suurs et al.   JOURNAL OF NUCLEAR MEDICINE

Endocytosis in cellular uptake of drug delivery vectors: Molecular aspects in drug development

(2020) Zuzanna Kaźmierczak et al.   BIOORGANIC & MEDICINAL CHEMISTRY

A Mucin 16 bispecific T cell–engaging antibody for the treatment of ovarian cancer

(2019) Alison Crawford et al.   Science Translational Medicine

Is there a place and role for endocytic TCR signaling?

(2019) Loredana Saveanu et al.   IMMUNOLOGICAL REVIEWS

Proteomic analyses of ECM during pancreatic ductal adenocarcinoma progression reveal different contributions by tumor and stromal cells

(2019) Chenxi Tian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Relative Target Affinities of T-Cell–Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model

(2018) Danielle Mandikian et al.   MOLECULAR CANCER THERAPEUTICS

Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety

(2018) Diego Ellerman   METHODS

CD3-bispecific antibody therapy turns solid tumors into inflammatory sites but does not install protective memory

(2018) Hreinn Benonisson et al.   MOLECULAR CANCER THERAPEUTICS

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models

(2017) Aran F. Labrijn et al.   Scientific Reports

Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM

(2016) F. J. Warnders et al.   JOURNAL OF NUCLEAR MEDICINE

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions

(2016) Tilman Schlothauer et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

(2015) Thomas Köhnke et al.   Journal of Hematology & Oncology

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

(2015) C Krupka et al.   LEUKEMIA

Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody

(2014) H. Xu et al.   Cancer Immunology Research

Characterization of a surrogate murine antibody to model anti-human CD3 therapies

(2013) Fabien Dépis et al.   mAbs

An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2

(2012) C Andrew Boswell et al.   BRITISH JOURNAL OF PHARMACOLOGY

Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors

(2011) S. I. Rudnick et al.   CANCER RESEARCH

Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance

(2008) Greg M. Thurber et al.   ADVANCED DRUG DELIVERY REVIEWS